US starts engaging drugmakers on putting Trump s MFN pricing into law

Director of Medicare and Deputy Administrator of CMS Chris Klomp speaks after U.S. President Donald Trump announced a deal with Pfizer to sell drugs at lower prices, in the Oval office of the White House in Washington, D.C., U.S., September 30, 2025. (REUTERS/Ken Cedeno)


March 19 (Reuters) - U.S. Health and Human Services chief counselor Chris Klomp said on Thursday the government has begun to read-in pharmaceutical companies on efforts to write into law President Donald Trump's most-favored-nation deals, aimed at aligning U.S. prescription drug costs with those in other wealthy countries.



(Reporting by Mariam Sunny in Bengaluru and Michael Erman in New York; Editing by Shilpi Majumdar)